J Cancer 2011; 2:331-332. doi:10.7150/jca.2.331

Short Report

Chimeric Antigen Receptor Therapy for B-cell Malignancies

David L Porter1,2✉, Michael Kalos1,3, Zhaohui Zheng1,3, Bruce Levine1,3, Carl June1,3

1. Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA
2. Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA
3. Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA

Abstract

We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.

Keywords: B-cell Malignancies, CART-19, Chimeric Antigen Receptor Therapy

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric Antigen Receptor Therapy for B-cell Malignancies. J Cancer 2011; 2:331-332. doi:10.7150/jca.2.331. Available from http://www.jcancer.org/v02p0331.htm